Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study Journal Article

   

Authors:	Ehmann, S.; Shay, K.; Zhou, Q.; Iasonos, A.; Sonoda, Y.; Gardner, G. J.; Long Roche, K.; Zammarrelli, W. A. 3rd; Yeoushoua, E.; O'Cearbhaill, R. E.; Zivanovic, O.; Chi, D. S.
Article Title:	Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study
Abstract:	Objective: To assess long-term outcomes of patients with advanced-stage ovarian cancer by treatment type. Methods: Patients with newly diagnosed stage III-IV ovarian cancer who underwent primary treatment at our tertiary cancer center from 01/01/2015–12/31/2015 were included. We reviewed electronic medical records for clinicopathological, treatment, and survival characteristics. Results: Of 153 patients, 88 (58%) had stage III and 65 (42%) stage IV disease. Median follow-up was 65.8 months (range, 3.6–75.3). Eighty-nine patients (58%) underwent primary debulking surgery (PDS), 50 (33%) received neoadjuvant chemotherapy followed by interval debulking surgery (IDS), and 14 (9%) received chemotherapy alone, without surgery (NSx). Median PFS to first recurrence was 26.2 months (range, 20.1–36.2), 13.5 months (range, 12–15.1), and 4.2 months (range, 1.1–5.8) in the PDS, IDS, and NSx groups, respectively (P < .001). At first recurrence/progression, 80 patients (72.7%) were treated with chemotherapy, 28 (25.5%) underwent secondary cytoreductive surgery (CRS) followed by chemotherapy, and 2 (1.8%) received no treatment. Seven patients (4.6%) underwent palliative surgery for malignant bowel obstruction. Overall, 62.7% received 1–3 lines of chemotherapy. The 5-year OS rates were 53.2% (95% CI: 44.7%–61%) for the entire cohort, 71.5% (95% CI: 60.2%–80%) for the PDS group, 35.2% (95% CI: 22.2–48.5%) for the IDS group, and 7.9% (95% CI: 0.5%–29.9%) for the NSx group. Conclusion: The longitudinal treatment modalities and outcomes of patients with advanced ovarian cancer described here can be useful for patient counseling, long-term planning, and future comparison studies. © 2022 Elsevier Inc.
Keywords:	ovarian cancer; cytoreductive surgery; recurrent ovarian cancer; survival data; treatment lines
Journal Title:	Gynecologic Oncology
Volume:	169
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	2023-02-01
Start Page:	118
End Page:	124
Language:	English
DOI:	10.1016/j.ygyno.2022.12.009
PROVIDER:	scopus
PUBMED:	36565685
PMCID:	PMC9928799
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144537802&doi=10.1016%2fj.ygyno.2022.12.009&partnerID=40&md5=1af532baecd3bdc266e29f638bb6b63c
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Dennis S. Chi -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/201868